MedEsthetics

JULY 19, 2024

Concerns about counterfeit Ozempic products and potential long-term effects has resulted in some pushback against GLP-1 drugs.

Safety 147

Safety Treatments 147

MedEsthetics

OCTOBER 30, 2023

The FDA recommends against the use of soft tissue fillers to increase breast size and the use of permanent fillers like silicone for cosmetic treatment, among other new guidelines.

Safety 148

Safety Treatments Injections 148

Dermatology Times

SEPTEMBER 26, 2023

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Safety 87

Safety Dermatitis Treatments 87

The Dermatology Digest

FEBRUARY 25, 2025

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed consistent safety and efficacy in patients with in moderate-to-severe plaque psoriasis for up to five years, new research shows. Moreover, the safety profile of deucravacitinib remained consistent through five years with no new safety signals identified.

Safety 36

Safety Clinic Sustainability Dermatology 36

The Dermatology Digest

MARCH 14, 2025

No safety signals emerged through Week 24. Icotrokinra has true game-changing potential, It has excellent tolerability, no GI side effects OR nausea) and the safety is excellent, she says, Hopefully, minimal or no lab testing will be needed.

Safety 36

Safety Injections Dermatology Clinic 36

Dermatology Times

MAY 16, 2024

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Safety 74

Safety Sustainability 74

Dermatology Times

OCTOBER 1, 2024

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Safety 74

Safety Clinic 74

MedEsthetics

NOVEMBER 5, 2024

Vice & Virtue's new skin care line addresses the epidemic of dangerous endocrine-disrupting chemicals with its commitment to providing skin safety at the micro level.

Safety 78

Safety 78

Dermatology Times

APRIL 1, 2025

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

Safety 58

Safety 58

AAAMS

JANUARY 3, 2025

The Role of Hands-On Training in Patient Safety In aesthetic medicine, patient safety is paramount. By emphasizing patient safety, hands-on training not only protects clients but also enhances a practitioners reputation and builds trust within their community. How does hands-on training improve patient safety?

Training 52

Training Safety Tools Injections 52

Dermatology Times

FEBRUARY 19, 2024

Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.

Dermatology 77

Dermatology Safety Clinic Medical 77

Dermatology Times

OCTOBER 8, 2024

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

Safety 74

Safety 74

Renee Rouleau

JULY 28, 2023

This really got me thinking—as Head of New Product Development at my company, it’s always been my responsibility to ensure the safety and quality of our products. This is why it’s incredibly important for manufacturers to follow proper safety and cleaning procedures to prevent contamination.

Skincare 195

Skincare Branding Safety Esthetician 195

Kim Gallo Esthetics

MAY 31, 2023

Higher quality Because medical-grade products are developed and tested by medical professionals, they are held to higher standards and must pass rigorous tests for safety and performance. FDA regulated Medical-grade skincare products are regulated by the FDA to ensure they meet safety and quality standards.

Medical Grade Skincare 195

Medical Grade Skincare Medical Skincare Esthetics 195

Dermatology Times

APRIL 8, 2025

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Safety 36

Safety Dermatology Innovations 36

Lipgloss and Aftershave

FEBRUARY 20, 2025

While the exact cause remains unknown, her case highlights a crucial truth: IV therapy isnt just a beauty treatmentits a medical procedure that requires precision, safety, and expertise. Quality & Safety Standards Choose PCAB-accredited pharmacies for top-quality compounding. Bottom line? Do it right, or dont do it at all.

Med Spa 52

Med Spa Therapy Legal Safety 52

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

Dermatology Times

APRIL 11, 2025

Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for (..)

Safety 36

Safety 36

MedEsthetics

JANUARY 8, 2024

The petition was filed on behalf of Public Citizen, a nonprofit consumer advocacy organization, and builds on a 2008 Public Citizen petition that asked the FDA to require the addition of the black-box warning on the labeling of Botox and related drugs.

Safety 78

Safety Injections 78

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

Dermatology Times

SEPTEMBER 24, 2024

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Safety 73

Safety Clinic 73

The Dermatology Digest

JANUARY 8, 2025

Without a physician on-site and immediately available, patient safety is compromised, as a physician with more in-depth, specialty-specific training would not be present to step in and assist if a complication occurs. Laurin Council, MD, MBA, ASDS/A President, in a news release.

Medical 36

Medical Social Media Safety Training 36

The Dermatology Digest

DECEMBER 29, 2024

We believe that the proposed testing techniques are appropriate methods to detect asbestos to help ensure the safety of talc-containing cosmetic products. We have carefully considered the scientific evidence and complex policy issues related to detecting and identifying asbestos in talc and talc-containing cosmetic products.

Cosmetic Products 74

Cosmetic Products Office Safety Dermatology 74

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb).

Portfolios 69

Portfolios Injections Office Safety 69

The Dermatology Digest

APRIL 18, 2025

The post FDA Approves First Targeted Therapy for CSU in More Than a Decade appeared first on The Dermatology Digest.

Therapy 45

Therapy Safety Dermatology Medical 45

AAAMS

NOVEMBER 13, 2024

The curriculum emphasizes safety, precision, and artistry, giving dental professionals the skills needed to achieve natural-looking results that enhance patient satisfaction. Dermal Filler Injection Training: In our dermal filler course, we focus on techniques for enhancing facial volume, contouring, and smoothing smile lines.

Injections 52

Injections Training Facials Surgery 52

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

Dermatology Times

APRIL 19, 2024

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

Technology 83

Technology Safety Clinic 83

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.

Safety 36

Safety Therapy 36

Dermatology Times

MARCH 21, 2025

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

NOVEMBER 19, 2024

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Safety 74

Safety Dermatitis 74

AAAMS

DECEMBER 16, 2024

AAAMS offers comprehensive courses that teach you the latest techniques while focusing on patient safety and satisfaction. Certification also ensures you meet industry standards for safety and effectiveness. Integrating these procedures begins with proper training and certification.

Chemical Peels 52

Chemical Peels Microneedling Social Media Surgery 52

Dermatology Times

APRIL 4, 2025

Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.

Safety 36

Safety Education Therapy 36

Dermatology Times

OCTOBER 1, 2024

Shawn Kwatra, MD, presented the Incyte data at EADV 2024.

Safety 74

Safety 74

Dermatology Times

MAY 30, 2024

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Sustainability 73

Sustainability Safety Clinic 73

Dermatology Times

DECEMBER 11, 2023

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 74

Safety Management Dermatitis 74

The Dermatology Digest

FEBRUARY 17, 2025

Many parents expressed concerns about the health and safety of non-surgical cosmetic procedures and worried that their child would either grow to regret them or would want more in the future. Woolford recommends parents do thorough research into the risks and benefits when considering whether to seek cosmetic procedures.

Social Media 57

Social Media Hair Removal Safety Surgery 57